S66 — Star Combo Pharma Income Statement
0.000.00%
Last trade - 00:00- AU$26.34m
- AU$17.52m
- AU$26.28m
- 87
- 76
- 79
- 94
Annual income statement for Star Combo Pharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | Interim Report |
| Standards: | AAS | AAS | AAS | AAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 27.1 | 23.9 | 25 | 26.3 | 28.2 |
| Cost of Revenue | |||||
| Gross Profit | 3.54 | 5.34 | 5.13 | 5.98 | 6.7 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 35.3 | 24.9 | 28.2 | 25.1 | 22.8 |
| Operating Profit | -8.21 | -0.957 | -3.22 | 1.18 | 5.43 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.46 | -1.08 | -3.45 | 1 | 5.31 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.88 | -0.696 | -4 | 0.747 | 5.25 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.88 | -0.696 | -4 | 0.747 | 5.25 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.88 | -0.696 | -4 | 0.747 | 5.25 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.028 | 0.002 | -0.008 | 0.006 | 0.039 |
| Dividends per Share |